The effects of a selective D4 dopamine receptor antagonist (L-745,870) in acutely psychotic inpatients with schizophrenia. D4 Dopamine Antagonist Group

Archives of General Psychiatry
M S KramerS A Reines

Abstract

Based mainly on the selective antagonism of clozapine at D4 compared with D2 dopamine receptors, hopes have run high that a selective D4 dopamine receptor antagonist might improve the pharmacological treatment of patients with schizophrenia. We report, to our knowledge, the first multicenter study of the antipsychotic potential of a highly specific D4 dopamine receptor antagonist (ie, L-745,870) in patients with acute schizophrenia. Thirty-eight acutely psychotic and neuroleptic responsive (by history) newly admitted inpatients with schizophrenia were randomized to 4 weeks of double-blind treatment (2:1) with either L-745,870 (n = 26), 15 mg/d, or placebo (n = 12) after a 3- to 5-day placebo run-in period. Overall, a greater percentage of patients receiving L-745,870 compared with patients receiving placebo discontinued the study for insufficient therapeutic response (32% vs 16%). At the end of 4 weeks by last observation carried forward analysis, the mean change from baseline to week 4 on the total Brief Psychiatric Rating Scale favored placebo (i.e., -8 points [-15% change from baseline] vs -1 point [-2% change from baseline] for placebo vs L-745,870, P = .09). Similar differences in favor of placebo in changes from baseline ...Continue Reading

Citations

Nov 16, 2013·CNS Spectrums·Yong Kee ChoiFrank I Tarazi
Mar 17, 2004·Biological Psychiatry·Mark H CorriganUNKNOWN Sonepiprazole Study Group
Apr 17, 2004·Proceedings of the National Academy of Sciences of the United States of America·Jorge D BrioniJames P Sullivan
May 15, 2013·Pharmacology, Biochemistry, and Behavior·Fabrizio SannaOsvaldo Giorgi
Feb 21, 2006·NeuroRx : the Journal of the American Society for Experimental NeuroTherapeutics·Gerard Marek, Kalpana Merchant
Jul 10, 2007·Schizophrenia Bulletin·John A Gray, Bryan L Roth
Sep 21, 2007·Current Psychiatry Reports·Mitsuru Toda, Anissa Abi-Dargham
Dec 4, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·Albert H C Wong, Hubert H M Van Tol
Dec 4, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·Herbert Y MeltzerJunji Ichikawa
Feb 19, 2010·Cellular and Molecular Life Sciences : CMLS·Pieter RondouKathleen Van Craenenbroeck
Mar 17, 2000·Brain Research. Brain Research Reviews·J C SchwartzP Sokoloff
Feb 15, 2012·Naunyn-Schmiedeberg's Archives of Pharmacology·Georges VauquelinPhilip Seeman
Sep 4, 2008·Expert Opinion on Emerging Drugs·Ofer AgidGary Remington
Oct 8, 2013·Biological Psychiatry·Paul J CockerCatharine A Winstanley
Dec 19, 2006·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Taylor Moran-GatesFrank I Tarazi
Jun 3, 2009·Journal of Neurochemistry·David F CummingsJohn A Schetz
Jul 1, 2006·Journal of Neuroscience Research·Taylor Moran-GatesFrank I Tarazi
Sep 13, 2005·Pharmacology, Biochemistry, and Behavior·Kaitlin E BrowmanGerard B Fox
May 17, 2005·Medical Hypotheses·Timothy P Olson
Oct 10, 2014·Psychiatry and Clinical Neurosciences·Ichiro KusumiYoshito Takahashi
Dec 6, 2011·Neuroscience and Biobehavioral Reviews·Zoran Vukadinovic, Ivana Rosenzweig
Dec 7, 2013·Behavioural Brain Research·Takeshi MuraiMutsuo Taiji
Sep 24, 2008·Handbook of Clinical Neurology·Richard B Mailman, Xuemei Huang
Mar 14, 2007·International Review of Neurobiology·Anissa Abi-Dargham
May 7, 2002·American Journal of Medical Genetics·Cristina CusinEnrico Smeraldi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here